Trifarotene
Aklief (trifarotene) is a small molecule pharmaceutical. Trifarotene was first approved as Aklief on 2019-10-04. It is used to treat acne vulgaris in the USA. The pharmaceutical is active against retinoic acid receptor gamma. In addition, it is known to target retinoic acid receptor beta and retinoic acid receptor alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Aklief
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aklief | New Drug Application | 2024-09-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acne vulgaris | EFO_0003894 | D000152 | L70 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRIFAROTENE, AKLIEF, GALDERMA LABS LP | |||
| 2024-10-04 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | 1 | 4 | 3 | — | 8 |
| Hyperpigmentation | D017495 | HP_0000953 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| T-cell lymphoma | D016399 | — | — | 1 | — | — | — | — | 1 |
| T-cell lymphoma peripheral | D016411 | — | — | 1 | — | — | — | — | 1 |
| T-cell lymphoma cutaneous | D016410 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trifarotene |
| INN | trifarotene |
| Description | Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; specifically, a fourth-generation selective retinoic acid receptor (RAR)-γ agonist.
|
| Classification | Small molecule |
| Drug class | arotinoid derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 895542-09-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707313 |
| ChEBI ID | — |
| PubChem CID | 11518241 |
| DrugBank | DB12808 |
| UNII ID | 0J8RN2W0HK (ChemIDplus, GSRS) |
Target
Alternate
RARB
RARB
RARA
RARA
Organism
Homo sapiens
Gene name
RARB
Gene synonyms
HAP, NR1B2
NCBI Gene ID
Protein name
retinoic acid receptor beta
Protein synonyms
HBV-activated protein, hepatitis B virus activated protein, Nuclear receptor subfamily 1 group B member 2, RAR-beta, RAR-epsilon, retinoic acid receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Rarb (218772)
retinoic acid receptor beta (P22605)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 125 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
91 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use